Search Results for: BNT162b2 vaccine

October 12, 2024October 12, 2024

BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.

Publication date: Oct 11, 2024 Due to safety concerns, patients were hesitant to receive a booster dose of COVID-19 vaccine. In this study, we investigated whether neovascular age-related macular degeneration ... Read more

September 22, 2024September 22, 2024

Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus.

Coronavirus Literature

Publication date: Sep 20, 2024 To evaluate both humoral and cellular immune responses to the COVID-19 messenger RNA (mRNA; BNT162b2) vaccine in patients with childhood-onset SLE (cSLE) compared with healthy ... Read more

September 22, 2024September 22, 2024

Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus.

Coronavirus Literature

August 25, 2024August 25, 2024

Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to

Coronavirus Literature

Publication date: Aug 24, 2024 With the future epidemiology and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uncertain, the use of safe and effective coronavirus disease 2019 (COVID-19) ... Read more

October 4, 2024October 4, 2024

Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July-December 2021.

Coronavirus Literature

Publication date: Aug 23, 2024 On 14 February 2021, Lebanon implemented nationwide vaccination, offering the Pfizer-BioNTech (BNT162b2) vaccine to adults over 50 years of age. We estimated the effectiveness of ... Read more

October 4, 2024October 4, 2024